|
" New agents for the treatment of acute lymphoblastic leukemia / "
Vaskar Saha, Pamela Kearns, editors
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
601326
|
| Doc. No
|
:
|
b430545
|
| Title & Author
|
:
|
New agents for the treatment of acute lymphoblastic leukemia /\ Vaskar Saha, Pamela Kearns, editors
|
| Page. NO
|
:
|
1 online resource (xviii, 338 pages)
|
| ISBN
|
:
|
9781441984593
|
|
|
:
|
: 1441984593
|
|
|
:
|
9781441984586
|
|
|
:
|
: 1441984585
|
|
|
:
|
: 9781441984586
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index
|
| Contents
|
:
|
New Agents for the Treatment of Acute Lymphoblastic Leukemia; Brief Overview; Acknowledgements; Contents; Contributors; Glossary; Chapter 1: The Need for New Agents; Chapter 2: Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia; Chapter 3: Preclinical Evaluation; Chapter 4: Design of Early-Phase Trials; Chapter 5: Strategies for Trial Design and Analyses; Chapter 6: An Overview on Animal Models of ALL; Chapter 7: Targeting Bcl-2 Family Proteins in Childhood Leukemia; Chapter 8: Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL
|
|
|
:
|
Chapter 9: Nucleoside AnaloguesChapter 10: FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia; Chapter 11: The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL; Chapter 12: Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia; Chapter 13: Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia; Chapter 14: Targeting Epigenetic Pathways in ALL; Chapter 15: Incorporating New Therapies into Frontline Protocols; Index
|
| Abstract
|
:
|
New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues
|
| Subject
|
:
|
Lymphoblastic leukemia-- Chemotherapy
|
| Subject
|
:
|
Drugs-- Design
|
| Subject
|
:
|
Drugs-- Research
|
| Subject
|
:
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma-- drug therapy
|
| Subject
|
:
|
Adolescent
|
| Subject
|
:
|
Antineoplastic Agents-- therapeutic use
|
| Subject
|
:
|
Child
|
| Subject
|
:
|
Clinical Trials as Topic
|
| Subject
|
:
|
Treatment Outcome
|
| Dewey Classification
|
:
|
616.99/419061
|
| LC Classification
|
:
|
RC280.L9N49 2011
|
| NLM classification
|
:
|
2011 G-881
|
|
|
:
|
WH 250
|
| Added Entry
|
:
|
Saha, Vaskar
|
|
|
:
|
Kearns, Pamela
|
| |